Summary To investigate the role of tumour-suppressor genes on the short arm of chromosome 3 in the mechanism of tumorigenesis in non-familial renal cell carcinoma, we analysed 55 paired blood-tumour DNA samples for allele loss on chromosome 3p and in the region of known or putative tumour-suppressor genes on chromosomes 5, 11, 17 and 22. Sixty-four per cent (35/55) of informative tumours showed loss of heterozygosity (LOH) of at least one locus on the short arm of chromosome 3, compared with only 13% at the p53 tumour-suppressor gene and 6% at 17q21. LOH at chromsome 5q21 and 22q was uncommon (2-3%). Detailed analysis of the regions of LOH on chromsome 3p suggested that, in addition to the VHL gene in chromosome 3p25-p26, mutations in one or more tumour-suppressor genes in chromosome 3pl3-p24 may be involved in the pathogenesis of sporadic renal cell carcinoma (RCC). We also confirmed previous suggestions that chromosome 3p allele loss is not a feature of papillary RCC (P<0.05).
Renal cell carcinoma (RCC) is an important human cancer whose aetiology is poorly understood. A small proportion of cases (approximately 2%) occur in patients with an inherited predisposition to RCC . The most common hereditary form of RCC is von Hippel-Lindau (VHL) disease, a dominantly inherited familial cancer syndrome predisposing to retinal and central nervous system haemangioblastomas, RCC and phaeochromocytoma (Maher et al., 1990a) . Affected patients not only have a high probability of developing RCC (70% at age 60 years), but also have an early age at onset and frequently develop multiple tumours (Maher et al., 1990a, b) . The gene for VHL disease has been mapped to chromosome 3p25-p26 (Seizinger et al., 1988; Hosoe et al., 1990; Seizinger et al., 1991a; Crossey et al., 1993a; Richards et al., 1993) and appears to function as a tumour-suppressor gene (Tory et al., 1989; Maher et al., 1990b; Crossey et al., 1993b; Latif et al., 1993) . Another familial RCC gene (RCCI) also maps to the short arm of chromosome 3: Cohen et al. (1979) reported a large family in which a balanced translocation between chromosome 3 and 8 was associated with a predisposition to early-onset multicentric RCC. The translocation breakpoint was at chromosome 3pl4, suggesting that mutations in two genes on chromsome 3p (VHL at 3p25-p26 and RCCI at 3pl4) may cause familial RCC.
Mutations in one or more tumour-suppressor genes on chromosome 3p have also been implicated in the pathogenesis of non-familial RCC . Shimuzu et al. (1990) found that the effect of introducing a normal chromosome 3p into a RCC cell line was to suppress its tumorigenicity. In addition, cytogenetic and molecular studies of sporadic RCC have shown frequent chromosome 3p deletions (Zbar et al., 1987; Kovacs et al., 1988; Bergerheim et al., 1989; Anglard et al., 1991; Van der Hout et al., 1991; Yamakawa et al., 1991) . The VHL and RCCI genes are candidate genes for non-familial RCC, but molecular genetic studies of chromosome 3p allele loss in sporadic RCC have yielded conflicting results about the localisation of the critical region of allele loss: Van der Hout et al. (1991 ) suggested 3p2l, Yamakawa et al. (1991 suggested 3pl4 and 3p2l, and Bergerheim et al. (1989) and Anglard et al. (1991) suggested chromosome 3p2l-p26, which would include the VHL disease locus. In addition to allele loss on chromosome 3p, loss of heterozygosity has been reported on several other chromosomes (including 5, 11 and 17) in sporadic RCC (Anglard et al., 1991; Morita et al., 1991 For the analysis of microsatellite markers (see Table I ) DNA was amplified by the polymerase chain reaction (PCR) as described previously (Crossey et al., 1993a, b) . DNA (50 ng) was amplified by PCR in 20 ftl reactions containing standard PCR buffer (10 mM Tris-Cl pH 8.8, 50 mM potassium chloride, 0.01% gelatin, 1.5 mM magnesium chloride, 10pmol of each primer, 0.1 pmol of end-labelled primer, 200 tLM each of dATP, dCTP, dGTP and dTTP, and 0.5 U of Taq polymerase. The samples were subjected to 20-30 PCR amplification cycles of 1 min denaturation at 94°C, 1 min annealing at 50-60°C and 1 min extension at 72°C. The PCR products were mixed with an equal volume of formamide loading buffer, heat denatured and then fractionated on a 6% polyacrylamide-6 M urea gel using a sequencing reaction as a size marker. Gels were dried and exposed for 1-3 days at -20°C.
Results

Chromosome 3p
All 55 tumours were informative at one or more loci on chromosome 3p, and overall 35 (64%) tumours showed LOH at one or more loci on chromosome 3p (see Table II 6, 10, 11, 16, 17, 20, 23, 27, 29, 35, 36, 38, 42, 48, 54); group b, 15 tumours had LOH on chromosome 3pl3-p24, but retention of heterozygosity in chromosome 3p25-p26 (tumours 4, 7, 12, 14, 15, 18, 19, 21, 22, 34, 37, 41, 44, 46, Firstly, if a single tumour-suppressor gene was involved it should be located centromeric to D3S1067 (see tumours 4, 21, 37, 44 and 46) and telomeric to D3S1076 (see tumour 34). However this conclusion is dependent on the deletion in tumour 34 overlapping with that in tumour 4, 21, 37, 44 or 46, and this could not be determined because DNA markers mapping between D3S1067 and D3S1076 were not available for study. The alternative conclusion would be that if the deletion in tumour 34 and those in tumours 4, 21, 37, 44 or 46 did not overlap then two tumour-suppressor genes, at 3pl4 and 3p2l, might be involved, as suggested by Yamakawa et al. (1991) . Following the isolation of the RCCI gene it will be possible to investigate the role of RCCI mutations in the pathogenesis of sporadic RCC. In addition, the isolation and accurate mapping of more microsatellite markers from chromosome 3pl4-p21 would enable the critical region of chromosome 3p allele loss in sporadic RCC to be defined more precisely. Human carcinogenesis is characteristically a multistep process in which mutations accumulate in a restricted number of tumour-suppressor genes and oncogenes. Although chromosome 3p allele loss is a frequent event in sporadic RCC, mutations in other tumour-suppressor genes may also occur. Morita et al. (1991) reported chromosome 17p and Sq allele loss in 5/24 and 5/17 RCCs respectively. However, Horii et al. (1992) did not detect any APC gene mutations in RCC with chromosome 5q LOH and suggested that another tumour-suppressor gene on chromosome 5q might contribute to the pathogenesis of RCC. The lower rates of LOH at chromosome 5q21 and 22q found by us (1/46 and 1/40 informative tumours respectively) are similar to those reported by van der Hout et al. (1991) (0/9 and 0/8 respectively). We detected LOH on chromosome 17 most frequently in the region of the p53 tumour-suppressor gene, although most tumours with LOH at p53 also demonstrated LOH at other chromosome 17 loci investigated. Although p53 mutations are the most frequent genetic abnormality in human cancer, the frequency of p53 involvement in sporadic RCC is less than in many other tumour types. We found LOH at the p53 locus in only 13% of informative tumours, which is similar to the findings of van der Hout et al. (1991) (12.5% LOH on 17p), Anglard et al. (1991) (11% LOH on chromosome 17), Torigoe et al. (1992) (10% p53 mutations) , Whaley et al. (1990) (7% p53 mutations) and Suzuki et al. (1992) (4.3% p53 mutations). It has been suggested that chromosome 3p allele loss is an early event in RCC, but that other tumour-suppressor gene mutations are involved in tumour progression. Anglard et al. (1991) found that LOH at chromosome lip and 13 was not present in localised tumours but was frequent in stage IV tumours. Kovacs et al. (1989) related the histopathological features of non-familial RCC with the molecular pathology, and suggested that chromosome 3p allele loss is infrequent in the papillary subgroup of RCC. Our findings also support this association.
The isolation of hereditary cancer genes will allow their role in the pathogenesis of non-familial RCC to be investigated by direct mutation analysis. Such studies should also elucidate the relationship between RCC tumour-suppressor genes and the molecular pathology of other human cancers, such as lung, breast, ovary, uterus and testis cancer, which show frequent chromosome 3p allele loss (Seizinger et al., 1991b) .
